Johnson & Johnson’s $4.3 billion purchase of Abbott Medical Optics led 58 transactions.
The femtosecond laser maker said it would continue operations without interruption.
The drug candidate is designed to reverse the gradual stiffening of the crystalline lens that occurs as individuals age.
The technology is being evaluated for its ability to reduce the burden associated with intraocular injection of anti-VEGF drugs.
CEO said the company planned to resubmit an NDA to the US FDA in Q1-2017.
Xiidra was made available in late August, and Shire reported Q3-2016 sales of $14 million.
The firm reported in September that the procedure was available in 61 countries.
Products that got the nod included the Abbott Symfony extended depth of field lens, Alcon CyPass Micro-Stent, and Allergan/AqueSys XEN Gel Stent.
Developer Ophthotech raised $740 million to advance the anti-PDGF agent.
Glaukos iStents surgeries exceeded filtration surgeries in the US for the second year in a row.
Premium lenses accounted for nearly a third of revenues because of significantly higher prices.
New standards require more postmarket surveillance and sharing of information.
Six events combined to increase options, lower prices for retinal patients.
Companies withdrew 83 percent of the applications awaiting action by the CFDA.
Treatments to watch include glaucoma drugs, automated capsulotomy devices, and a nasal neurostimulator.
Global revenues in the segment are expected to exceed $1.2 billion in 2017.
The proposal would have paid doctors a 2.5 percent add-on fee for drugs, plus a flat fee of $16.80 per day.
The companies have set an aggressive timeline, planning a commercial rollout in 2018.
This is the fifth FDA-approved indication for the anti-VEGF agent.
The system now can be used for LASIK patients with mixed astigmatism.
You are not currently logged in.
©2018 Market Scope
Lost your Password